EVP-6308

FORUM Pharmaceuticals Inc · Phase 1 active Small molecule

EVP-6308 is an investigational drug being developed by FORUM Pharmaceuticals Inc. It has completed Phase 1 trials assessing its safety, tolerability, pharmacokinetics, and pharmacodynamics in subjects with schizophrenia. The drug aims to modulate the effects of antipsychotic regimens and has shown promise in early studies.

At a glance

Generic name	EVP-6308
Sponsor	FORUM Pharmaceuticals Inc
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

EVP-6308 CI brief — competitive landscape report
EVP-6308 updates RSS · CI watch RSS
FORUM Pharmaceuticals Inc portfolio CI